Clinical and laboratory features of patients
| . | All* (n = 351) . | t(11;14)(q13;q32) (n = 53) . | Other (n = 283) . |
|---|---|---|---|
| Median age, y (range) | 62.6 (34-84) | 62.2 (34-79) | 62.6 (34-84) |
| Descriptive features, % | |||
| Gender, male, female | 62.1, 37.9 | 67.9, 32.1 | 60.8, 39.2 |
| ECOG performance status 0-1, 2-4 | 86.3, 13.7 | 90.6, 9.4 | 85.9, 14.1 |
| Plasmacytoma present | 10.0 | 5.7 | 11.4 |
| Weight loss, more than 10% | 7.2 | 7.5 | 7.6 |
| Hypercalcemia, serum calcium more than 12 mg/dL | 24.5 | 23.1 | 24.6 |
| Serum monoclonal protein† | 82.9 | 71.7 | 84.8 |
| Urine monoclonal protein† | 74.2 | 69.2 | 75.6 |
| Bone disease | 79.1 | 81.0 | 78.4 |
| X-ray lytic lesions‡ | 79.4 | 78.6 | 78.8 |
| Light chain1-153 | |||
| κ | 64.8 | 60.5 | 66.5 |
| λ | 35.2 | 39.5 | 33.5 |
| Median laboratory values (range) | |||
| Hemoglobin, g/dL | 10.7 (5.1-15.8) | 10.5 (6.2-15.4) | 10.7 (5.1-15.8) |
| Leukocytes, × 106/mL | 5.8 (1.6-56.0) | 6.2 (2.5-12.1) | 5.8 (1.6-56) |
| Peripheral blood plasma cells, % | 0 (0-93) | 0 (0-10) | 0 (0-93) |
| Bone marrow plasma cells by flow, % | 0.25 (0.01-0.86) | 0.29 (0.02-0.86) | 0.24 (0.01-0.80) |
| Platelets, × 106/mL | 233 (40-637) | 237 (85-535) | 233 (40-637) |
| Bone marrow plasma cells, % | 43 (2-99) | 50 (8-96) | 44 (2-99) |
| Creatinine, mg/dL | 1.2 (0.4-4.9) | 1.3 (0.5-4.7) | 1.2 (0.4-4.9) |
| Calcium, mg/dL | 9.5 (4.5-15.8) | 9.4 (4.5-15.6) | 9.5 (7.1-15.8) |
| Albumin, g/L | 3.5 (1.1-5.4) | 3.6 (2-5.2) | 3.5 (1.1-5.4) |
| Bilirubin, mg/dL | 0.4 (0.1-1.4) | 0.4 (0.1-1.4) | 0.4 (0.1-1.2) |
| CD4+ cells, % of PBL | 25 (0-73) | 29 (0-73) | 25 (0-68) |
| CD19+ cells, % of PBL | 13 (0-79) | 10 (0-72) | 14 (0-79) |
| C-reactive protein, mg/dL | 0.3 (0.1-20.3) | 0.4 (0.1-5.6) | 0.3 (0.1-20.3) |
| sIL-6R, ng/mL | 187 (50-1067) | 157 (65-800) | 187 (50-80) |
| . | All* (n = 351) . | t(11;14)(q13;q32) (n = 53) . | Other (n = 283) . |
|---|---|---|---|
| Median age, y (range) | 62.6 (34-84) | 62.2 (34-79) | 62.6 (34-84) |
| Descriptive features, % | |||
| Gender, male, female | 62.1, 37.9 | 67.9, 32.1 | 60.8, 39.2 |
| ECOG performance status 0-1, 2-4 | 86.3, 13.7 | 90.6, 9.4 | 85.9, 14.1 |
| Plasmacytoma present | 10.0 | 5.7 | 11.4 |
| Weight loss, more than 10% | 7.2 | 7.5 | 7.6 |
| Hypercalcemia, serum calcium more than 12 mg/dL | 24.5 | 23.1 | 24.6 |
| Serum monoclonal protein† | 82.9 | 71.7 | 84.8 |
| Urine monoclonal protein† | 74.2 | 69.2 | 75.6 |
| Bone disease | 79.1 | 81.0 | 78.4 |
| X-ray lytic lesions‡ | 79.4 | 78.6 | 78.8 |
| Light chain1-153 | |||
| κ | 64.8 | 60.5 | 66.5 |
| λ | 35.2 | 39.5 | 33.5 |
| Median laboratory values (range) | |||
| Hemoglobin, g/dL | 10.7 (5.1-15.8) | 10.5 (6.2-15.4) | 10.7 (5.1-15.8) |
| Leukocytes, × 106/mL | 5.8 (1.6-56.0) | 6.2 (2.5-12.1) | 5.8 (1.6-56) |
| Peripheral blood plasma cells, % | 0 (0-93) | 0 (0-10) | 0 (0-93) |
| Bone marrow plasma cells by flow, % | 0.25 (0.01-0.86) | 0.29 (0.02-0.86) | 0.24 (0.01-0.80) |
| Platelets, × 106/mL | 233 (40-637) | 237 (85-535) | 233 (40-637) |
| Bone marrow plasma cells, % | 43 (2-99) | 50 (8-96) | 44 (2-99) |
| Creatinine, mg/dL | 1.2 (0.4-4.9) | 1.3 (0.5-4.7) | 1.2 (0.4-4.9) |
| Calcium, mg/dL | 9.5 (4.5-15.8) | 9.4 (4.5-15.6) | 9.5 (7.1-15.8) |
| Albumin, g/L | 3.5 (1.1-5.4) | 3.6 (2-5.2) | 3.5 (1.1-5.4) |
| Bilirubin, mg/dL | 0.4 (0.1-1.4) | 0.4 (0.1-1.4) | 0.4 (0.1-1.2) |
| CD4+ cells, % of PBL | 25 (0-73) | 29 (0-73) | 25 (0-68) |
| CD19+ cells, % of PBL | 13 (0-79) | 10 (0-72) | 14 (0-79) |
| C-reactive protein, mg/dL | 0.3 (0.1-20.3) | 0.4 (0.1-5.6) | 0.3 (0.1-20.3) |
| sIL-6R, ng/mL | 187 (50-1067) | 157 (65-800) | 187 (50-80) |
Differences between patients with and without the translocation were not statistically significant with the exception of those related to the serum monoclonal protein level (see text).
ECOG indicates Eastern Cooperative Oncology Group; PBL, peripheral blood lymphocytes; sIL-6R, soluble interleukin-6 receptor level.
Includes patients with failed FISH assay.
For the serum monoclonal protein this meant a concentration greater than 10 g/L, and for the urinary protein this meant a urinary protein concentration greater than 0.2 g/24 h.
If x-ray bone abnormalities were present.
If serum monoclonal protein component was present.